EMMA (Emmaus Life Sciences) Cyclically Adjusted Book per Share: $-2.59 (As of Mar. 2026)


What is Emmaus Life Sciences Cyclically Adjusted Book per Share?

Emmaus Life Sciences EMMA Cyclically Adjusted Book per Share is $-2.59 as of Mar. 2026. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Emmaus Life Sciences's adjusted book value per share for the three months ended in Mar. 2026 was $-0.968. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-2.59 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 48.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 70.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 45.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Emmaus Life Sciences was 79.50% per year. The lowest was -107.90% per year. And the median was -1.30% per year.

As of today (2026-06-27), Emmaus Life Sciences's current stock price is $0.01. Emmaus Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $-2.59. Emmaus Life Sciences's Cyclically Adjusted PB Ratio of today is .


Emmaus Life Sciences  (OTCPK:EMMA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Emmaus Life Sciences Cyclically Adjusted Book per Share Related Terms


Emmaus Life Sciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Cyclically Adjusted Book per Share Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,044.64 -37.87 -14.01 -12.07 -5.14

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.00 -9.67 -7.81 -5.14 -2.59

EMMA vs CERO, AGTX, WINT: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Cyclically Adjusted PB Ratio falls into.



Emmaus Life Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emmaus Life Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.968/330.2130*330.2130
=-0.968

Current CPI (Mar. 2026) = 330.2130.

Emmaus Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 -83.011 241.018 -113.731
201609 -3.287 241.428 -4.496
201612 2.040 241.432 2.790
201703 1.252 243.801 1.696
201706 -2.253 244.955 -3.037
201709 6.342 246.819 8.485
201712 2.930 246.524 3.925
201803 2.525 249.554 3.341
201806 2.983 251.989 3.909
201809 3.255 252.439 4.258
201812 1.720 251.233 2.261
201903 1.359 254.202 1.765
201906 1.795 256.143 2.314
201909 -0.368 256.759 -0.473
201912 -0.228 256.974 -0.293
202003 -0.097 258.115 -0.124
202006 -0.286 257.797 -0.366
202009 -0.130 260.280 -0.165
202012 -0.105 260.474 -0.133
202103 -0.257 264.877 -0.320
202106 -0.190 271.696 -0.231
202109 -0.306 274.310 -0.368
202112 -0.435 278.802 -0.515
202203 -0.452 287.504 -0.519
202206 -0.699 296.311 -0.779
202209 -0.758 296.808 -0.843
202212 -0.688 296.797 -0.765
202303 -0.706 301.836 -0.772
202306 -0.653 305.109 -0.707
202309 -0.677 307.789 -0.726
202312 -0.772 306.746 -0.831
202403 -0.867 312.332 -0.917
202406 -0.893 314.175 -0.939
202409 -0.842 315.301 -0.882
202412 -0.884 315.605 -0.925
202503 -0.918 319.799 -0.948
202506 -0.872 322.561 -0.893
202509 -0.931 324.800 -0.947
202512 -0.906 324.054 -0.923
202603 -0.968 330.213 -0.968

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-2.59 mean?
Emmaus Life Sciences (EMMA) has a Cyclically Adjusted Book per Share of $-2.59 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Cyclically Adjusted Book per Share too high?
Emmaus Life Sciences' current Cyclically Adjusted Book per Share is $-2.59.
How does Emmaus Life Sciences' Cyclically Adjusted Book per Share compare to CERO and AGTX?
Emmaus Life Sciences' Cyclically Adjusted Book per Share of $-2.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Cyclically Adjusted Book per Share is $-2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Cyclically Adjusted Book per Share is $-2.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Cyclically Adjusted Book per Share is $-2.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.